文献速递慢病管理预防保健、筛查与疫苗

魁北克社区成人多病共存、多重用药与一级预防的横断面研究

Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study.
PubMed 文献 · Fam Pract · 2019-01-01

该研究基于加拿大魁北克PRECISE队列随访数据,对971名社区成人进行横断面分析,发现30.3%存在多病共存、31.9%存在多重用药。多病共存与多重用药呈强关联,且无心血管疾病史者中部分使用他汀或抗血小板药进行一级预防,可能加剧多重用药并引发安全性担忧。

要点

  • 社区成人中多重用药患病率为31.9%,多病共存患病率为30.3%。
  • 慢性病数量越多,多重用药风险越高,三种及以上慢性病者 adjusted OR 达25.31。
  • 无心血管疾病史者中16.2%使用抗血小板药、28.5%使用他汀进行一级预防。

核心结论

  • 魁北克社区成人中多重用药患病率高,且与多病共存呈强关联。
  • 无心血管疾病史者中使用他汀或抗血小板药进行一级预防可能贡献于多重用药,并引发安全性问题。

研究设计与样本

  • 加拿大魁北克PRECISE队列随访数据的横断面分析,样本量n=971。
  • 多病共存定义为存在三种及以上慢性病,多重用药定义为自我报告同时使用五种及以上药物。
  • 一级预防概念化为无心血管疾病诊断报告的情况下使用他汀或低剂量抗血小板药。

主要发现

  • 研究对象平均年龄56.7±11.6岁,女性占62.5%,30.3%有多病共存,31.9%有多重用药(n=971)。
  • 最常用药物为他汀类、肾素-血管紧张素系统抑制剂和精神药物。
  • 与无慢性病者相比,有一种慢性病者多重用药 adjusted OR 为2.78(95%CI: 1.23-6.28),两种者为8.88(95%CI: 4.06-19.20),三种及以上者为25.31(95%CI: 11.77-54.41),P<0.001。
  • 无心血管疾病史者中,16.2%使用抗血小板药,28.5%使用他汀。
  • 多病共存与一级预防使用抗血小板药 adjusted OR 为2.98(95%CI: 1.98-4.48,P<0.001),使用他汀 adjusted OR 为3.76(95%CI: 2.63-5.37,P<0.001)。

临床怎么用

  • 在社区成人中应关注多重用药问题,尤其是多病共存患者。
  • 对于无心血管疾病史者使用他汀或抗血小板药进行一级预防时,需权衡获益与多重用药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy carries the risk of adverse events, especially in people with multimorbidity. OBJECTIVE: To investigate the prevalence of polypharmacy in community-dwelling adults, the association of multimorbidity with polypharmacy and the use of medications for primary prevention. METHODS: Cross-sectional analysis of the follow-up data from the Program of Research on the Evolution of a Cohort Investigating Health System Effects (PRECISE) in Quebec, Canada. Multimorbidity was defined as the presence of three or more chronic diseases and polypharmacy as self-reported concurrent use of five or more medications. Primary prevention was conceptualized as the use of statin or low-dose antiplatelets without a reported diagnostic of cardiovascular disease. RESULTS: Mean age 56.7 ± 11.6, 62.5% female, 30.3% had multimorbidity, 31.9% had polypharmacy (n = 971). The most common drugs used were statins, renin-angiotensin system inhibitors and psychotropics. Compared to participants without any chronic disease, the adjusted odds ratios (ORs) for having polypharmacy were 2.78 [95% confidence interval (CI): 1.23-6.28] in those with one chronic disease, 8.88 (95% CI: 4.06-19.20) in those with two chronic diseases and 25.31 (95% CI: 11.77-54.41) in those with three or more chronic diseases, P < 0.001. In participants without history of cardiovascular diseases, 16.2% were using antiplatelets and 28.5% were using statins. Multimorbidity was associated with increased likelihood of using antiplatelets (adjusted OR: 2.98, 95% CI: 1.98-4.48, P < 0.001) and statins (adjusted OR: 3.76, 95% CI: 2.63-5.37, P < 0.001) for primary prevention. CONCLUSION: There was a high prevalence of polypharmacy in community-dwelling adults in Quebec and a strong association with multimorbidity. The use of medications for primary prevention may contribute to polypharmacy and raise questions about safety.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Nguyen TN, Ngangue P, Haggerty J, et al. Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study. Fam Pract. 2019. PMID: 31104072. doi:10.1093/fampra/cmz023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。